Abstract
Background: Several phase 3 clinical trials have demonstrated the benefit of CDK4/6 inhibitors (iCDK4/6) associated with endocrine therapy on survival outcomes, with a manageable toxicity profile. Despite the high prevalence of breast cancer patients over 65 years, this population is usually underrepresented in trials, which leads to an extrapolation of data from younger and healthier patients. However, the geriatric population is heterogeneous in terms of comorbidities and performance status. The aim of this study is to evaluate the clinical benefit (CB) and toxicities of ribociclib (R) and palbociclib (P) in the elderly population of our Center.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
